Sanofi - Aventis Groupe: Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase

Related Keywords

Japan ,United States ,Paris ,France General ,France ,America ,Eva Schaefer Jansen ,Arnaud Delepine ,Felix Lauscher ,Georged Yancopoulos ,Vesna Tosic ,Hannah Kwagh ,Nathalie Pham ,Sally Bain ,Naimish Patel ,Exchange Commission ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Head Of Global Development ,Dupilumab Development Program ,Teva Pharmaceutical Industries Ltd ,Global Development ,Chief Scientific Officer ,Worst Itch Numeric Rating Scale ,Global Assessment ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Digital Media ,Regeneron Pharmaceuticals ,Product Candidates ,Teva Pharmaceutical Industries ,Sanofi ,Eventis ,Roupe ,Second ,Positive ,Hase ,Dupixent ,Dupilumab ,Trial ,Onfirms ,Significant ,Improvements ,Patients ,Prurigo ,Nodularis ,